JNJ‐63733657 (Janssen) is a humanized IgG1 monoclonal antibody that was selected for targeting the microtubule‐binding region of tau and disrupting cell‐to‐cell propagation of aggregated tau.[74, 95] Its murine precursor was derived by immunizing mice with tau paired‐helical filaments isolated from AD human brain (Figure 4b).[81, 96] JNJ‐63733657 was tested in two phase I clinical trials. This evidence concerns the gene MAPT and Alzheimer disease.